Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo
The DOI matches its Crossref record; 20 of the 24 references it cites were found in a registry or an index.
Abstract
Objectives To determine whether baseline prostate-specific antigen (PSA), in addition to prostate volume, is associated with long-term changes in symptoms and urinary flow rate.Methods Three thousand forty men with benign prostatic hyperplasia enrolled in the PLESS trial were randomly assigned to finasteride 5 mg or placebo for 4 years. Symptoms and flow rate were assessed every 4 months, and data were analyzed by dividing the patients into three groups by baseline PSA tertiles (0 to 1.3, 1.4 to 3.2, and 3.3 ng/mL or greater) and baseline prostate volume tertiles (14 to 41, 42 to 57, and 58 to 1 50 mL).Results After the initial placebo effect, a slow deterioration in symptoms over time was observed in the placebo-treated men with a baseline PSA 1.4 ng/mL or greater. However, placebo-treated men in the lowest PSA tertile (less than 1.4 ng/mL) had sustained symptomatic improvement that was not seen in placebo-treated men in the higher tertiles (P<0.001). In all finasteride-treated groups, there was initial improvement followed by maintenance or continued symptom improvement over time (approximately 3 to 3.5 points by the end of 4 years). The differences in symptom score improvement between placebo and finasteride were marginal for men with baseline PSA levels less than 1.4 ng/mL (P = 0.128) but were highly significant for men with PSA levels 1.4 ng/mL or greater (P<0.001). Urinary flow rate results were similar to those observed for symptoms. Analysis of symptom and flow rate data by prostate volume tertiles in a 10% subset of men yielded similar results, namely a deterioration of symptoms and flow rate in the two higher tertiles treated with placebo (greater than 41 mL) and a sustained improvement in all three groups of finasteride-treated patients.Conclusions Baseline PSA and prostate volume are good predictors of long-term symptomatic and flow rate changes. Baseline PSA levels of 1.4 ng/mL or greater and enlarged prostate glands predict the best long-term response to finasteride compared with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The data in this dataset is representative of the clinical variability and challenges encountered in clinical settings.”
From V-Net: Fully Convolutional Neural Networks for Volumetric Medical Image Segmentation (2016) · cites this paper as [7]
In the citing paper
“The test set was representative of the clinical variability encountered in prostate scans in real clinical settings [7].”
From V-Net: Fully Convolutional Neural Networks for Volumetric Medical Image Segmentation (2016) · cites this paper as [7]
Citations
Cites
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271701 · Cited by 1,124
Self-citationMcConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Self-citationThe Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350801 · Cited by 792
Barry, M. J., Williford, W. O., Chang, Y., Machi, M., Jones, K. M., Walker-Corkery, E., & Lepor, H. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)66780-6 · Cited by 510
Boyle, P., Lawrence Gould, A., & Roehrborn, C. G. (1996) · Urology · doi:10.1016/s0090-4295(96)00353-6 · Cited by 469
Self-citationRoehrborn, C. G., Boyle, P., Gould, A. L., & Waldstreicher, J. (1999) · Urology · doi:10.1016/s0090-4295(98)00655-4 · Cited by 390
Self-citationRoehrborn, C. G., McConnell, J. D., Lieber, M., Kaplan, S., Geller, J., Malek, G. H., Castellanos, R., Coffield, S., Saltzman, B., Resnick, M., et al. (1999) · Urology · doi:10.1016/s0090-4295(98)00654-2 · Cited by 333
Self-citationROEHRBORN, C. G., McCONNELL, J., BONILLA, J., ROSENBLATT, S., HUDSON, P. B., MALEK, G. H., SCHELLHAMMER, P. F., BRUSKEWITZ, R., MATSUMOTO, A. M., HARRISON, L. H., et al. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67962-1 · Cited by 265
Self-citationNickel, J. C., Fradet, Y., Boake, R., Pommerville, P. J., Perreault, J., Afridi, S. K., & ELHILALI, M. M. (1996) · Europe PMC (PubMed Central) · Cited by 225
Research works printed but not linked: 2
- Barry, 1995, Measuring disease-specific health status in men with benign prostatic hyperplasia, Med Care, 33, AS145, AS155
- Boyle, 1997, Baseline serum PSA levels predict degree of symptom improvement following therapy of BPH with finasteride, J Urol, 157, 134A
Cited by
V-Net: Fully Convolutional Neural Networks for Volumetric Medical Image Segmentation
Milletari, F., Navab, N., & Ahmadi, S.-A. (2016) · 2016 Fourth International Conference on 3D Vision (3DV) · doi:10.1109/3dv.2016.79 · Cited by 11,931
Gratzke, C., Bachmann, A., Descazeaud, A., Drake, M. J., Madersbacher, S., Mamoulakis, C., Oelke, M., Tikkinen, K. A. O., & Gravas, S. (2015) · European Urology · doi:10.1016/j.eururo.2014.12.038 · Cited by 1,010
AUA PRACTICE GUIDELINES COMMITTEE (2003) · Journal of Urology · doi:10.1097/01.ju.0000078083.38675.79 · Cited by 844
Roehrborn, C. G., Siami, P., Barkin, J., Damião, R., Major-Walker, K., Nandy, I., Morrill, B. B., Gagnier, R. P., & Montorsi, F. (2010) · European Urology · doi:10.1016/j.eururo.2009.09.035 · Cited by 788
Self-citationRoehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Self-citation
Metadata
- Authors
- Roehrborn, C. G., Boyle, P., Bergner, D., Gray, T., Gittelman, M., Shown, T., Melman, A., Bracken, R. B., deVere White, R., Taylor, A., Wang, D., & Waldstreicher, J.
- Affiliations
- University of California, Davis (US)
- European Institute of Oncology (IT)
- Tampa Bay Medical Research (US)
- Lovelace Medical Center (US)
- South Florida Medical Research (US)
- Montefiore Medical Center (US)
- University of Cincinnati (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Roehrborn, Claus G.
- Venue
- Urology
- Publisher
- Elsevier BV
- Published
- 1999-10
- Volume
- 54
- Issue
- 4
- Pages
- 662-669
- ISSN
- 0090-4295 (ISSN-L)
- OpenAlex
- W2148027243
- Cited by
- 233
- References
- 24
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 8 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 12 · 2012: 5
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- prostate-specific antigen, prostate volume, benign prostatic hyperplasia, finasteride, urinary flow rate, lower urinary tract symptoms, predictors of treatment response, placebo effect, alpha-blockers
- MeSH terms
- Enzyme Inhibitors, Humans, Male, Middle Aged, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Time Factors, Urodynamics, Prostate-Specific Antigen, Finasteride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. https://app.cochat.ai/papers/10.1016/s0090-4295(99)00232-0
- The paper
- Roehrborn, C. G., Boyle, P., Bergner, D., Gray, T., Gittelman, M., Shown, T., Melman, A., Bracken, R. B., deVere White, R., Taylor, A., Wang, D., & Waldstreicher, J. (1999). Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology. https://doi.org/10.1016/s0090-4295(99)00232-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.